Chronocort® Phase 1 Study Given Regulatory Approval | Investor or Media Relations | Diurnal | Dedicated to developing hormone therapeutics

About Us
About Us
Founded in 2004, DIURNAL^® , a NEUROCRINE BIOSCIENCES^® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
Company Profile
History
Executive Team
Research
Research
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
Clinical Trial Data Access Request
Partnering
Partnering
Partnering and business development is integral to our strategy of building a leading pharmaceutical company. We forge creative partnerships with other innovative companies that advance our business.
Partnering Objectives
Existing Partners
Investors
Investors
Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc
PR Archive
PR Archive
View all historical press releases in the News section. Effective 1 November 2022, Diurnal Limited has been acquired by Neurocrine Biosciences Inc.
News
Transparency
Transparency
Diurnal is committed to transparency in its interactions. Diurnal commits to following relevant pharmaceutical codes and has published details of its transfers of value.
Overview
France
Careers
Careers
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision.
Why Join Us?
Current Vacancies

Chronocort® Phase 1 Study Given Regulatory Approval

24th February 2010

Diurnal, the physiological hormone replacement company, today announced that it has received Medicines and Healthcare products Regulatory Agency (MHRA) and Ethics Approval to carry out an open label, randomised, single dose crossover study in healthy volunteers of its lead product Chronocort®.

Chronocort® is a modified release hydrocortisone formulation for the treatment of Congenital Adrenal Hyperplasia and Adrenal Insufficiency both chronic, life-long diseases. The outcomes of this Phase 1 study aimed to compare the pharmacokinetics of Chronocort® to immediate release hydrocortisone and to determine the dose proportionality of Chronocort®.

The study will be carried out at Simbec Research located in Merthyr Tydfil (Wales, UK), and is expected to start during Q2, 2010.

Prof Richard Ross, Chief Scientific Officer, said:

"It is a tremendous credit to the Diurnal and Simbec teams to have completed and achieved regulatory submission in such a short space of time. We have begun enrolment in the study which we hope to start imminently".